2
Registered trials
1
Recruiting
2
Unique sponsors
4
Unique IMPs
1
Commercial trials
Drug classes (ATC)
V
Various (ATC V)
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
RAF/BRAF inhibitor
1 substance
Kinase inhibitor
1 substance
Phase II:
1
Phase I/II:
1
Phase II
1 trial-
RecruitingIovance Biotherapeutics Inc. Commercial(3R)-N-[3-[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUOROPHENYL]-3-FLUOROPYRROLIDINE-1-SULFONAMIDE; COBICISTAT
Phase I/II
1 trial-
EndedMedical Center - University Of Freiburg AcademicSORAFENIB; TRAMETINIB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Iovance Biotherapeutics Inc. | Commercial | 1 | Phase II | 1 |
| Medical Center - University Of Freiburg | Academic | 1 | Phase I/II | 0 |
New trials by year
2020
1
2023
1